Eli Lilly and Company (LLY) Holdings Lessened by First Personal Financial Services

First Personal Financial Services lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,729 shares of the company’s stock after selling 20 shares during the period. First Personal Financial Services’ holdings in Eli Lilly and were worth $554,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after purchasing an additional 59,978,664 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after purchasing an additional 2,181,701 shares during the period. Winslow Capital Management LLC boosted its holdings in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after purchasing an additional 1,719,538 shares during the period. Harbour Capital Advisors LLC boosted its holdings in shares of Eli Lilly and by 7,919.1% in the second quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock valued at $20,721,000 after purchasing an additional 1,684,072 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after purchasing an additional 1,441,200 shares during the period. Institutional investors and hedge funds own 75.72% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) Holdings Lessened by First Personal Financial Services” was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.thestockobserver.com/2017/10/13/eli-lilly-and-company-lly-holdings-lessened-by-first-personal-financial-services.html.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.86 EPS.

LLY has been the subject of a number of research reports. Jefferies Group LLC reiterated a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a report on Monday, September 11th. BMO Capital Markets reiterated an “underperform” rating and issued a $71.00 price target (down previously from $73.00) on shares of Eli Lilly and in a report on Wednesday, September 6th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $105.00 price target (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a report on Monday, July 17th. Finally, Morgan Stanley reiterated a “hold” rating and issued a $86.00 price target on shares of Eli Lilly and in a report on Friday, September 15th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and an average price target of $88.57.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 990,000 shares of company stock valued at $82,949,650. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply